ERBB2 and neoplasm: Consistent with results from HCC1954 xenograft study, the combined treatment with ML364 and 17-AAG displayed the strongest suppression against xenograft tumor growth, which was accompanied with potent ErbB2 downregulation (Fig. 7b–d).